Involvement of Ribosomal Protein L11 Expression in Sensitivity of Gastric Cancer Against 5-FU

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Mar 21

PMID 32194724

Citations 8

Authors

Takuto Kawahata

Kohichi Kawahara

Michiko Shimokawa

Akie Sakiyama

Takehiro Shiraishi

Kentaro Minami

Masatatsu Yamamoto

Yoshinari Shinsato

Kazunari Arima

Toshiyuki Hamada

Tatsuhiko Furukawa

Affiliations

Soon will be listed here.

Abstract

5-Fluorouracil (5-FU) is widely used in the treatment of various types of solid cancer. Our study showed that ribosomal protein L11 (RPL11) was a crucial factor affecting sensitivity of gastric cancer to 5-FU, implying that RPL11 expression is a potential biomarker for predicting 5-FU sensitivity. Kaplan-Meier survival analysis indicated that high expression in gastric cancer patients treated with 5-FU was significantly associated with good prognosis. It was therefore investigated whether RPL11 affected the sensitivity of gastric cancer against 5-FU using four human gastric cancer cell lines, MKN45 (wild-type gene), NUGC4 (wild-type), MKN7 (mutated), and KE39 cells (mutated). assays demonstrated that RPL11 knockdown in gastric cancer cell lines carrying the wild-type gene attenuated 5-FU-induced cell growth suppression and activation of the P53 pathway, but not in cells carrying mutated , suggesting that 5-FU suppresses tumor progression via RPL11-mediated activation of the P53 pathway in gastric cancer. The present study provides a potential therapeutic strategy for improving 5-FU resistance in gastric cancer by elevating RPL11 expression.

Citing Articles

Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers.

Ishihara Y, Nakamura K, Nakagawa S, Okamoto Y, Yamamoto M, Furukawa T Int J Mol Sci. 2022; 23(24).

PMID: 36555627 PMC: 9784028. DOI: 10.3390/ijms232415986.

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia.

Nakagawa S, Kawahara K, Okamoto Y, Kodama Y, Nishikawa T, Kawano Y Cancers (Basel). 2022; 14(20).

PMID: 36291909 PMC: 9601175. DOI: 10.3390/cancers14205127.

RPS3 Promotes the Metastasis and Cisplatin Resistance of Adenoid Cystic Carcinoma.

Rui X, Huang Z, Chen R, Chen Y, Wang Y, Huang Z Front Oncol. 2022; 12:804439.

PMID: 35847905 PMC: 9280127. DOI: 10.3389/fonc.2022.804439.

Deregulation of ribosomal proteins in human cancers.

El Khoury W, Nasr Z Biosci Rep. 2021; 41(12).

PMID: 34873618 PMC: 8685657. DOI: 10.1042/BSR20211577.

Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma.

Charwudzi A, Meng Y, Hu L, Ding C, Pu L, Li Q PeerJ. 2021; 9:e12394.

PMID: 34760386 PMC: 8570165. DOI: 10.7717/peerj.12394.

References

Yang Y, Nakagawa H, Tetreault M, Billig J, Victor N, Goyal A . Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res. 2011; 71(20):6475-84. PMC: 3193554. DOI: 10.1158/0008-5472.CAN-11-1702. View

Osaki M, Tatebe S, Goto A, Hayashi H, Oshimura M, Ito H . 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis. 1997; 2(2):221-6. DOI: 10.1023/a:1026476801463. View

HOUGHTON J, Tillman D, Harwood F . Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res. 1995; 1(7):723-30. View

Kanamaru R, Kakuta H, Sato T, Ishioka C, WAKUI A . The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol. 1986; 17(1):43-6. DOI: 10.1007/BF00299864. View

Sun X, Dai M, Lu H . 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem. 2007; 282(11):8052-9. DOI: 10.1074/jbc.M610621200. View

Ajani J . Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. DOI: 10.1634/theoncologist.10-90003-49. View

Dai M, Arnold H, Sun X, Sears R, Lu H . Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 2007; 26(14):3332-45. PMC: 1933407. DOI: 10.1038/sj.emboj.7601776. View

Dai M, Zeng S, Jin Y, Sun X, David L, Lu H . Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004; 24(17):7654-68. PMC: 506971. DOI: 10.1128/MCB.24.17.7654-7668.2004. View

Sampath D, Rao V, Plunkett W . Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003; 22(56):9063-74. DOI: 10.1038/sj.onc.1207229. View

10.

Wang C, Li X, Zhang J, Ge Z, Chen H, Hu J . EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression. Onco Targets Ther. 2018; 11:7853-7864. PMC: 6225849. DOI: 10.2147/OTT.S180131. View

11.

Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

12.

Nabeya Y, Loganzo Jr F, Maslak P, Lai L, de Oliveira A, Schwartz G . The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer. 1995; 64(1):37-46. DOI: 10.1002/ijc.2910640109. View

13.

Pickard M, Dive C, Kinsella A . Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Br J Cancer. 1995; 72(6):1389-96. PMC: 2034080. DOI: 10.1038/bjc.1995.519. View

14.

Jin A, Itahana K, Okeefe K, Zhang Y . Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol. 2004; 24(17):7669-80. PMC: 506972. DOI: 10.1128/MCB.24.17.7669-7680.2004. View

15.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

16.

Dai M, Lu H . Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004; 279(43):44475-82. DOI: 10.1074/jbc.M403722200. View

17.

Lohrum M, Ludwig R, Kubbutat M, Hanlon M, Vousden K . Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003; 3(6):577-87. DOI: 10.1016/s1535-6108(03)00134-x. View

18.

Petak I, Tillman D, HOUGHTON J . p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res. 2000; 6(11):4432-41. View

19.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

20.

Dai M, Shi D, Jin Y, Sun X, Zhang Y, Grossman S . Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 2006; 281(34):24304-13. PMC: 1783840. DOI: 10.1074/jbc.M602596200. View